Sclerostin antibody increases bone volume and enhances implant fixation in a rat model

Journal of Bone and Joint Surgery

Volumn 94, Issue 18, 2012, Pages 1670-1680

  Virdi, Amarjit S ^a   Liu, Min ^b   Sena, Kotaro ^a   Maletich, James ^a   McNulty, Margaret ^a   Ke, Hua Zhu ^b   Sumner, Dale R ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; SCLEROSTIN ANTIBODY; SODIUM CHLORIDE; STAINLESS STEEL; TITANIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE; BONE STRENGTH; CONTROL GROUP; CORTICAL BONE; FEMORAL ANGIOGRAPHY; FIXATION DEVICE; HISTOPATHOLOGY; IMPLANT; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; TRABECULAR BONE; VOLUMETRY;

EID: 84867570636     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.K.00344     Document Type: Article

References (72)

1. Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91:128-33.
2. Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am. 2005;87:1487-97. (Pubitemid 40917748)
3. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-5. (Pubitemid 46564282)
4. Hungerford DS, Mont MA. Revision of the femoral component: proximal porous coating. In: Callaghan JJ, Rosenberg AG, Rubash HE. The adult hip. Philadelphia: Lippincott-Raven; 1998. p 1503-13.
5. Callaghan JJ, Johnston RC. Revision of the femoral component: cement. In: Callaghan JJ, Rosenberg AG, Rubash HE. The adult hip. Philadelphia: Lippincott-Raven; 1998. p 1515-26.
6. Mavrogenis AF, Dimitriou R, Parvizi J, Babis GC. Biology of implant osseointegration. J Musculoskelet Neuronal Interact. 2009;9:61-71.
7. Sumner DR, Virdi AS. Bioactive coatings for implant fixation. In: Berry DJ, Lieberman JR, editors. Surgery of the hip. New York, Elsevier, 2010.
8. Bobyn JD, Jacobs JJ, Tanzer M, Urban RM, Aribindi R, Sumner DR, Turner TM, Brooks CE. The susceptibility of smooth implant surfaces to periimplant fibrosis and migration of polyethylene wear debris. Clin Orthop Relat Res. 1995;311:21-39.
9. Sumner DR, Turner TM, Urban RM, Turek T, Seeherman H, Wozney JM. Locally delivered rhBMP-2 enhances bone ingrowth and gap healing in a canine model. J Orthop Res. 2004;22:58-65. (Pubitemid 38035446)
10. Aspenberg P, Jeppsson C, Wang JS, Boström M. Transforming growth factor beta and bone morphogenetic protein 2 for bone ingrowth: a comparison using bone chambers in rats. Bone. 1996;19:499-503.
11. Cochran DL, Schenk R, Buser D, Wozney JM, Jones AA. Recombinant human bone morphogenetic protein-2 stimulation of bone formation around endosseous dental implants. J Periodontol. 1999;70:139-50.
12. Bragdon CR, Doherty AM, Rubash HE, Jasty M, Li XJ, Seeherman H, Harris WH. The efficacy of BMP-2 to induce bone ingrowth in a total hip replacement model. Clin Orthop Relat Res. 2003;417:50-61. (Pubitemid 37499510)
13. Sigurdsson TJ, Fu E, Tatakis DN, Rohrer MD, Wikesjö UM. Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. Clin Oral Implants Res. 1997;8:367-74. (Pubitemid 127688511)
14. Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br. 2001;83:437-40. (Pubitemid 32390361)
15. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805-14. (Pubitemid 38375200)
16. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-76. (Pubitemid 37522584)
17. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842-4. Epub 2005 Aug 25.
18. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res. 2010;25:1897-904.
19. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005;36:943-7. (Pubitemid 40797994)
20. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-9. (Pubitemid 351768804)
21. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24:1651-61.
22. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-7. Epub 2005 Mar 18.
23. Johnson ML, Harnish K, Nusse R, Van Hul W. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res. 2004;19:1749-57. Epub 2004 Aug 23.
24. Ott SM. Sclerostin and Wnt signaling - the pathway to bone strength. J Clin Endocrinol Metab. 2005;90:6741-3. (Pubitemid 41759344)
25. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-88.
26. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
27. Sandberg MM, Aro HT, Vuorio EI. Gene expression during bone repair. Clin Orthop Relat Res. 1993;289:292-312. (Pubitemid 23124826)
28. 'Nakase T, Nomura S, Yoshikawa H, Hashimoto J, Hirota S, Kitamura Y, Oikawa S, Ono K, Takaoka K. Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing. J Bone Miner Res. 1994;9:651-9.
29. Bostrom MP, Lane JM, Berberian WS, Missri AA, Tomin E, Weiland A, Doty SB, Glaser D, Rosen VM. Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res. 1995;13:357-67.
30. Yoshimura Y, Nomura S, Kawasaki S, Tsutsumimoto T, Shimizu T, Takaoka K. Colocalization of noggin and bone morphogenetic protein-4 during fracture healing. J Bone Miner Res. 2001;16:876-84. (Pubitemid 32332297)
31. Yu Y, Yang JL, Chapman-Sheath PJ, Walsh WR. TGF-beta, BMPS, and their signal transducing mediators, Smads, in rat fracture healing. J Biomed Mater Res. 2002;60:392-7.
32. Campisi P, Hamdy RC, Lauzier D, Amako M, Rauch F, Lessard ML. Expression of bone morphogenetic proteins during mandibular distraction osteogenesis. Plast Reconstr Surg. 2003;111:201-8; discussion 209-10.
33. Kloen P, Di Paola M, Borens O, Richmond J, Perino G, Helfet DL, Goumans MJ. BMP signaling components are expressed in human fracture callus. Bone. 2003;33:362-71. (Pubitemid 37103253)
34. Niikura T, Hak DJ, Reddi AH. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res. 2006;24:1463-71. (Pubitemid 44083262)
35. Zhong N, Gersch RP, Hadjiargyrou M. Wnt signaling activation during bone regeneration and the role of Dishevelled in chondrocyte proliferation and differentiation. Bone. 2006;39:5-16. Epub 2006 Feb 3.
36. Issack PS, Helfet DL, Lane JM. Role of Wnt signaling in bone remodeling and repair. HSS J. 2008;4:66-70. Epub 2007 Dec 8.
37. Chen Y, Alman BA. Wnt pathway, an essential role in bone regeneration. J Cell Biochem. 2009;106:353-62.
38. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res. 2010. 2010;26:1012-21.
39. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25:2412-8.
40. De Ranieri A, Virdi AS, Kuroda S, Shott S, Dai Y, Sumner DR. Local application of rhTGF-beta2 modulates dynamic gene expression in a rat implant model. Bone. 2005;36:931-40. Epub 2005 Mar 24.
41. De Ranieri A, Virdi AS, Kuroda S, Shott S, Leven RM, Hallab NJ, Sumner DR. Local application of rhTGF-beta2 enhances peri-implant bone volume and boneimplant contact in a rat model. Bone. 2005;37:55-62. (Pubitemid 40848418)
42. De Ranieri A, Virdi AS, Kuroda S, Healy KE, Hallab NJ, Sumner DR. Saline irrigation does not affect bone formation or fixation strength of hydroxyapatite/tricalcium phosphate-coated implants in a rat model. J Biomed Mater Res B Appl Biomater. 2005;74:712-7. (Pubitemid 41076942)
43. Kuroda S, Virdi AS, Li P, Healy KE, Sumner DR. A low-temperature biomimetic calcium phosphate surface enhances early implant fixation in a rat model. J Biomed Mater Res A. 2004;70:66-73. (Pubitemid 38849813)
44. Ishizaka M, Tanizawa T, Sofue M, Dohmae Y, Endo N, Takahashi HE. Bone particles disturb new bone formation on the interface of the titanium implant after reaming of the marrow cavity. Bone. 1996;19:589-94. (Pubitemid 27035837)
45. Hara T, Hayashi K, Nakashima Y, Kanemaru T, Iwamoto Y. The effect of hydroxyapatite coating on the bonding of bone to titanium implants in the femora of ovariectomised rats. J Bone Joint Surg Br. 1999;81:705-9.
46. Schmidmaier G, Wildemann B, Schwabe P, Stange R, Hoffmann J, Südkamp NP, Haas NP, Raschke M. A new electrochemically graded hydroxyapatite coating for osteosynthetic implants promotes implant osteointegration in a rat model. J Biomed Mater Res. 2002;63:168-72. (Pubitemid 34263861)
47. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-28. (Pubitemid 20136185)
48. Ho JE, Barber TA, Virdi AS, Sumner DR, Healy KE. The effect of enzymatically degradable IPN coatings on peri-implant bone formation and implant fixation. J Biomed Mater Res A. 2007;81:720-7. (Pubitemid 46786904)
49. Suva LJ, Seedor JG, Endo N, Quartuccio HA, Thompson DD, Bab I, Rodan GA. Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res. 1993;8:379-88. (Pubitemid 23095903)
50. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16.
51. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468-86.
52. Berzins A, Sumner DR. Implant pushout and pullout tests. In: An YH, Draughn RA. Mechanical testing of bone and the bone-implant interface. Boca Raton: CRC Press; 2000. p 463-76.
53. Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am. 1995;77:1135-47.
54. Sumner DR, Turner TM, Urban RM, Leven RM, Hawkins M, Nichols EH, McPherson JM, Galante JO. Locally delivered rhTGF-beta2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury. J Orthop Res. 2001;19:85-94. (Pubitemid 32288640)
55. Sumner DR, Turner TM, Cohen M, Losavio P, Urban RM, Nichols EH, McPherson JM. Aging does not lessen the effectiveness of TGFbeta2-enhanced bone regeneration. J Bone Miner Res. 2003;18:730-6. (Pubitemid 36899323)
56. Amsel S, Maniatis A, Tavassoli M, Crosby WH. The significance of intramedullary cancellous bone formation in the repair of bone marrow tissue. Anat Rec. 1969;164:101-11.
57. Patt HM, Maloney MA. Bone marrow regeneration after local injury: a review. Exp Hematol. 1975;3:135-48.
58. Bab IA. Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption. Bone. 1995;17(4 Suppl): 437S-441S.
59. Gazit D, Zilberman Y, Turgeman G, Zhou S, Kahn A. Recombinant TGF-beta1 stimulates bone marrow osteoprogenitor cell activity and bone matrix synthesis in osteopenic, old male mice. J Cell Biochem. 1999;73:379-89. (Pubitemid 29198012)
60. Liang CT, Barnes J, Seedor JG, Quartuccio HA, Bolander M, Jeffrey JJ, Rodan GA. Impaired bone activity in aged rats: alterations at the cellular and molecular levels. Bone. 1992;13:435-41.
61. Tanaka H, Barnes J, Liang CT. Effect of age on the expression of insulin-like growth factor-I, interleukin-6, and transforming growth factor-beta mRNAs in rat femurs following marrow ablation. Bone. 1996;18:473-8. (Pubitemid 26152311)
62. Wise JK, Sena K, Vranizan K, Pollock JF, Healy KE, Hughes WF, Sumner DR, Virdi AS. Temporal gene expression profiling during rat femoral marrow ablation-induced intramembranous bone regeneration. PLoS One. 2010;5. pii: e12987.
63. Gabet Y, Kohavi D, Voide R, Mueller TL, Müller R, Bab I. Endosseous implantanchorage is critically dependent on mechanostructural determinants of peri-implant bone trabeculae. J Bone Miner Res. 2010;25:575-83.
64. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab. 2007;92:747-53. (Pubitemid 46465635)
65. Dayer R, Badoud I, Rizzoli R, Ammann P. Defective implant osseointegration under protein undernutrition: prevention by PTH or pamidronate. J Bone Miner Res. 2007;22:1526-33. (Pubitemid 351229323)
66. Skripitz R, Aspenberg P. Early effect of parathyroid hormone (1-34) on implant fixation. Clin Orthop Relat Res. 2001;392:427-32. (Pubitemid 33054976)
67. Skripitz R, Böhling S, Rüther W, Aspenberg P. Stimulation of implant fixation byparathyroid hormone (1-34)-A histomorphometric comparison of PMMA cement and stainless steel. J Orthop Res. 2005;23:1266-70. Epub 2005 Jun 16.
68. Skripitz R, Johansson HR, Ulrich SD, Werner A, Aspenberg P. Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats. J Orthop Sci. 2009;14:138-43. Epub 2009 Apr 1.
69. Dayer R, Brennan TC, Rizzoli R, Ammann P. PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet. Osteoporos Int. 2010;21:957-67. Epub 2009 Oct 27.
70. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact. 2006;6:358-9. (Pubitemid 46099716)
71. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3:e2942.
72. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-43. (Pubitemid 32184286)